Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

Verteporfin is being discussed for its potential to regrow hair and heal scars, possibly aiding hair transplants or replacing them. Some users are skeptical about its effectiveness, while others suggest combining it with microneedling for better results.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

Red light therapy with dual wavelengths (650nm and 850nm) can stimulate hair regrowth without DHT blockers. Consistent use of a panel with these wavelengths has shown positive results in hair regrowth.

A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.